KemPharm to Report Second Quarter 2022 Financial Results
August 04 2022 - 7:30AM
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a
specialty pharmaceutical company focused on the discovery,
development and commercialization of novel treatments for rare
central nervous system (CNS), neurodegenerative and lysosomal
storage diseases, today announced that the Company will host a
conference call and live audio webcast on Thursday, August 11,
2022, at 5:00 p.m. ET, to discuss its corporate and financial
results for the second quarter 2022.
The audio webcast with slide presentation will
be accessible via the Investor Relations section of the Company’s
website, http://investors.kempharm.com/. An archive of the webcast
and presentation will be available for 90 days beginning at
approximately 6:00 p.m. ET, on August 11, 2022.
Additionally, interested participants and
investors may access conference call by dialing either:
-
(800) 245-3047 (U.S.)
-
(203) 518-9765 (International)
-
Conference ID: KMPHQ222
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery, development and commercialization of
novel treatments for rare central nervous system (CNS),
neurodegenerative and lysosomal storage diseases. KemPharm has a
diverse product portfolio, combining a clinical-stage development
pipeline with revenue-generating NDA-stage and commercial assets.
The pipeline includes arimoclomol, an orally-delivered,
first-in-class treatment for Niemann-Pick disease type C (NPC), and
KP1077, which the company is developing as a treatment for
idiopathic hypersomnia (IH), a rare neurological sleep disorder,
and narcolepsy. In addition, the U.S. Food and Drug Administration
(FDA) has approved AZSTARYS®, a once-daily treatment for ADHD in
patients aged six years and older containing KemPharm’s prodrug,
serdexmethylphenidate (SDX), which is being commercialized by
Corium, Inc. in the U.S., and APADAZ®, an immediate-release
combination product containing benzhydrocodone, KemPharm’s prodrug
of hydrocodone, and acetaminophen, which is being commercialized by
KVK-Tech, Inc. in the U.S. For more information on KemPharm and its
pipeline of product candidates visit www.kempharm.com or connect
with us on Twitter, LinkedIn, Facebook and YouTube.
KemPharm Contacts:
Tiberend Strategic Advisors, Inc. Jason Rando/Daniel
Kontoh-Boatengjrando@tiberend.com dboateng@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Sep 2023 to Sep 2024